Naturewill Biotechnology

Naturewill Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative immune cell therapies. The company focuses on chimeric antigen receptor T-cell (CAR-T) treatments for hematological malignancies and refractory solid tumors. Its lead candidate, NW-01, is a BCMA-targeted CAR-T therapy currently being evaluated in Phase 1/2 clinical trials for the treatment of relapsed or refractory multiple myeloma. Naturewill leverages its proprietary cell engineering platforms to enhance the persistence, efficacy, and safety of cell-based medicines. The company is also advancing multi-target CAR-T programs, such as dual CD19/CD22 therapies, to address tumor antigen escape and improve patient outcomes.